Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 04 - 23 symbols : Bmy save search
Hematology/Oncology (Cancer) Approvals & Safety Notifications
Published: 2021-04-23 (Crawled : 18:42) - fda.gov
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
RIGL | $1.07 1.91% 1.87% 810K
|
Health Technology
| Email alert
Add to watchlist
ILMN | $117.43 0.63% 0.63% 1.4M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
| Email alert
Add to watchlist
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
| Email alert
Add to watchlist
CLVS | $0.0812 -3.94%
|
Health Technology
| Email alert
Add to watchlist
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
| Email alert
Add to watchlist
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
| Email alert
Add to watchlist
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
AGIO | $29.52 0.31% 0.3% 750K
|
Health Technology
| Email alert
Add to watchlist
VSTM | $9.86 -3.62% -3.75% 150K
|
Health Technology
| Email alert
Add to watchlist
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
AVEO | $15.0 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
YMAB | $15.15 1.0% 0.99% 470K
|
Health Technology
| Email alert
Add to watchlist
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
| Email alert
Add to watchlist
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
| Email alert
Add to watchlist
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
| Email alert
Add to watchlist
cancer approval
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
Published: 2021-04-23 (Crawled : 18:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.03%
H: 0.95%
C: -0.44%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.03%
H: 1.24%
C: 0.8%
positive phase 3 psoriasis
April 27-29, 2021: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement - 04/27/2021 - 04/29/2021
Published: 2021-04-23 (Crawled : 17:05) - fda.gov
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.03%
H: 0.95%
C: -0.44%
drug
Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
Published: 2021-04-23 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.03%
H: 0.95%
C: -0.44%
myeloid leukemia positive therapy leukemia chmp acute myeloid leukemia
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
Published: 2021-04-23 (Crawled : 11:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.03%
H: 0.95%
C: -0.44%
treatment positive approval chmp nivolumab
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.